Abstracts tagged "TNFi and registries"

Abstract Number: 2446 • 2019 ACR/ARP Annual Meeting
Gender Differences in Psoriatic Arthritis – Impact on Tumor Necrosis Factor Inhibitors Persistence and Response
Elsa Vieira-Sousa¹, Mónica Eusébio ², Pedro Ávila-Ribeiro ³, Nikita Khmelinskii ⁴, Rita Cruz-Machado ⁵, Teresa Martins Rocha ⁶, Miguel Bernardes ⁷, Daniela Santos-Faria ⁸, Joana Leite Silva ⁸, Helena Santos ⁹, Cláudia Miguel ¹⁰, Pedro Carvalho ¹¹, Tiago Costa ¹², Lídia Teixeira ¹³, Tiago Meirinhos ¹⁴, Patrícia Nero ¹⁵, João Eurico Fonseca ³ and Maria José Santos ¹⁶, ¹Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, ²Portuguese Society of Rheumatology, Lisbon, Portugal, ³Rheumatology and Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa; Centro Académico de Medicina de Lisboa; Lisbon, Portugal., Lisbon, Portugal, ⁴Rheumatology and Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Lisbon, Portugal., Lisbon, Portugal, ⁵Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHULN; Lisboa, Portugal. Centro Académico de Medicina de Lisboa, Portugal., Lisbon, Portugal, ⁶Rheumatology Department, Porto, Porto, Portugal, ⁷Rheumatology, Centro Hospitalar de São João, Porto, Portugal, Porto, Portugal, ⁸Rheumatology Department, ULSAM, Ponte de Lima, Portugal, ⁹Instituto Português de Reumatologia (IPR), Lisbon, Portugal, ¹⁰Instituto Português de Reumatologia, Lisbon, Portugal, ¹¹Rheumatology Department, CHUC and CHUA, Faro, Portugal, ¹²Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental; CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Lisbon., Lisbon, Portugal, ¹³Rheumatology Department, HGO, Almada, Portugal, ¹⁴Rheumatology Department, CHBV, Aveiro, Portugal, ¹⁵Hospital CUF Descobertas, Lisbon, Portugal, ¹⁶Rheumatology department, Hospital Garcia de Orta, Almada, Portugal
Background/Purpose: The impact of gender on tumor necrosis factor inhibitors (TNFi) effectiveness has been poorly studied in Psoriatic Arthritis (PsA) patients. The objective of this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].